• +1-646-491-9876
    • +91-20-67278686

    Search

    Axillary Hyperhidrosis - Pipeline Review, H1 2017

    Axillary Hyperhidrosis - Pipeline Review, H1 2017

    • Report Code ID: RW0001767490
    • Category Pharmaceuticals
    • No. of Pages 53
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Axillary Hyperhidrosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2017, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

    Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 1 respectively.

    Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Axillary Hyperhidrosis - Overview
    Axillary Hyperhidrosis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Axillary Hyperhidrosis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Axillary Hyperhidrosis - Companies Involved in Therapeutics Development
    Allergan Plc
    Brickell Biotech Inc
    Dermira Inc
    Dr. August Wolff GmbH & Co KG Arzneimittle
    GlaxoSmithKline Plc
    TheraVida Inc
    Axillary Hyperhidrosis - Drug Profiles
    (oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    botulinum toxinA - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glycopyrrolate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glycopyrronium tosylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sofpironium bromide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    umeclidinium bromide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Axillary Hyperhidrosis - Dormant Projects
    Axillary Hyperhidrosis - Discontinued Products
    Axillary Hyperhidrosis - Product Development Milestones
    Featured News & Press Releases
    Mar 21, 2017: Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
    Mar 17, 2017: Dermira to Present Data on Glycopyrronium Tosylate Clinical Program at Annual Maui Derm Meeting
    Mar 03, 2017: Dermira Presents New Data in Primary Axillary Hyperhidrosis at American Academy of Dermatology 2017 Annual Meeting
    Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
    Feb 27, 2017: Dermira Data from DRM04 Clinical Program to Be Presented at American Academy of Dermatology Annual Meeting
    Oct 13, 2016: Dermira to Present Data from DRM04 Clinical Program at Fall Clinical Dermatology Conference
    Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
    Oct 01, 2016: Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
    Sep 28, 2016: Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
    Jun 01, 2016: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis
    Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
    Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
    Jan 07, 2016: Dermira Provides DRM04 Development Program Update
    Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
    Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Axillary Hyperhidrosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Axillary Hyperhidrosis - Pipeline by Allergan Plc, H1 2017
    Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H1 2017
    Axillary Hyperhidrosis - Pipeline by Dermira Inc, H1 2017
    Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
    Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Axillary Hyperhidrosis - Pipeline by TheraVida Inc, H1 2017
    Axillary Hyperhidrosis - Dormant Projects, H1 2017
    Axillary Hyperhidrosis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Axillary Hyperhidrosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Allergan Plc
    Brickell Biotech Inc
    Dermira Inc
    Dr. August Wolff GmbH & Co KG Arzneimittle
    GlaxoSmithKline Plc
    TheraVida Inc

    Request for Sample

    Report Url http://www.reportsweb.com//axillary-hyperhidrosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//axillary-hyperhidrosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//axillary-hyperhidrosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments